HABA LaboratoriesInc Balance Sheet Health
Financial Health criteria checks 5/6
HABA LaboratoriesInc has a total shareholder equity of ¥8.3B and total debt of ¥2.3B, which brings its debt-to-equity ratio to 27.4%. Its total assets and total liabilities are ¥12.4B and ¥4.0B respectively. HABA LaboratoriesInc's EBIT is ¥240.0M making its interest coverage ratio 18.5. It has cash and short-term investments of ¥4.0B.
Key information
27.4%
Debt to equity ratio
JP¥2.28b
Debt
| Interest coverage ratio | 18.5x |
| Cash | JP¥3.99b |
| Equity | JP¥8.34b |
| Total liabilities | JP¥4.02b |
| Total assets | JP¥12.36b |
Recent financial health updates
Recent updates
What Type Of Returns Would HABA LaboratoriesInc's(TYO:4925) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Mar 09
These 4 Measures Indicate That HABA LaboratoriesInc (TYO:4925) Is Using Debt Reasonably Well
Feb 19Should You Be Impressed By HABA LaboratoriesInc's (TYO:4925) Returns on Capital?
Feb 01Is HABA Laboratories,Inc. (TYO:4925) A Smart Choice For Dividend Investors?
Jan 13
HABA Laboratories,Inc.'s (TYO:4925) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Dec 25What Kind Of Investors Own Most Of HABA Laboratories,Inc. (TYO:4925)?
Dec 07A Look At HABA LaboratoriesInc's (TYO:4925) Share Price Returns
Nov 19Financial Position Analysis
Short Term Liabilities: 4925's short term assets (¥8.9B) exceed its short term liabilities (¥2.9B).
Long Term Liabilities: 4925's short term assets (¥8.9B) exceed its long term liabilities (¥1.1B).
Debt to Equity History and Analysis
Debt Level: 4925 has more cash than its total debt.
Reducing Debt: 4925's debt to equity ratio has increased from 21.7% to 27.4% over the past 5 years.
Debt Coverage: 4925's debt is well covered by operating cash flow (30.1%).
Interest Coverage: 4925's interest payments on its debt are well covered by EBIT (18.5x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 01:54 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HABA Laboratories,Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kenji Sakai | Mizuho Securities Co., Ltd. |